According to a press release, FDA regenerative medicine advanced therapy has been awarded to DiscGenics Inc. for its injectable disc therapy for patients with symptomatic lumbar disc disease.
According to the release, injectable disc therapy (IDCT), has the potential to increase disc size, decrease low back pain, and reduce the use of pain medication in patients with lumbar disc disease.
“This designation represents a critical validation of our novel approach to utilizing a manufactured live progenitor cell population derived from
